Steven Ledger - Serina Therapeutics Interim Director
| SER Stock | 4.79 0.64 15.42% |
Director
Steven Ledger is Interim Director of Serina Therapeutics
| Age | 65 |
| Address | 601 Genome Way, Huntsville, AL, United States, 35806 |
| Phone | 256 327 9630 |
| Web | https://serinatherapeutics.com |
Steven Ledger Latest Insider Activity
Tracking and analyzing the buying and selling activities of Steven Ledger against Serina Therapeutics stock is an integral part of due diligence when investing in Serina Therapeutics. Steven Ledger insider activity provides valuable insight into whether Serina Therapeutics is net buyers or sellers over its current business cycle. Note, Serina Therapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Serina Therapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Steven Ledger over three months ago Acquisition by Steven Ledger of 376388 shares of Serina Therapeutics at 7.4 subject to Rule 16b-3 |
Serina Therapeutics Management Efficiency
The company has Return on Asset of (0.4529) % which means that on every $100 spent on assets, it lost $0.4529. This is way below average. Serina Therapeutics' management efficiency ratios could be used to measure how well Serina Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of 12/18/2024, Return On Tangible Assets is likely to drop to -1.37. In addition to that, Return On Capital Employed is likely to grow to -1.56. At this time, Serina Therapeutics' Total Assets are relatively stable compared to the past year. As of 12/18/2024, Non Current Assets Total is likely to grow to about 11.8 M, while Return On Tangible Assets are likely to drop (1.37).Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Tench Coxe | Artisan Partners Asset | 62 | |
| Robert Clark | Minerals Technologies | 57 | |
| MD D | Lipocine | 66 | |
| John Carmola | Minerals Technologies | 65 | |
| Marc Robinson | Minerals Technologies | 59 | |
| Christopher Genualdi | NETGEAR | N/A | |
| Alison Deans | Minerals Technologies | 59 | |
| Alexander Whitelam | SEI Investments | N/A | |
| Carolyn Pittman | Minerals Technologies | 57 | |
| Andres Gluski | Waste Management | 63 | |
| Kathleen Mazzarella | Waste Management | 61 | |
| Maryrose Sylvester | Waste Management | 55 | |
| Jennifer Barbetta | Artisan Partners Asset | 47 | |
| Joseph Breunig | Minerals Technologies | 59 | |
| William Plummer | Waste Management | 62 | |
| Victoria Holt | Waste Management | 63 | |
| Franklin Feder | Minerals Technologies | 70 | |
| Donald Winter | Minerals Technologies | 72 | |
| Stephanie DiMarco | Artisan Partners Asset | 62 | |
| Matthew Barger | Artisan Partners Asset | 62 | |
| Frank Clark | Waste Management | 73 | |
Management Performance
| Return On Asset | -0.45 |
Serina Therapeutics Leadership Team
Elected by the shareholders, the Serina Therapeutics' board of directors comprises two types of representatives: Serina Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Serina. The board's role is to monitor Serina Therapeutics' management team and ensure that shareholders' interests are well served. Serina Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Serina Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| EunJae CPA, Interim Officer | ||
| Michael Bentley, Chief CoFounder | ||
| Milton Harris, CoFounder Board | ||
| Steven Ledger, Interim Director | ||
| Tacey Viegas, Chief Officer | ||
| Balkrishan Gill, Executive Chairman | ||
| Srini Tenjarla, Manufacturing Chemistry |
Serina Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Serina Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -0.45 | ||||
| Profit Margin | (2.21) % | ||||
| Operating Margin | (75.80) % | ||||
| Current Valuation | 62.84 M | ||||
| Shares Outstanding | 8.88 M | ||||
| Shares Owned By Insiders | 58.14 % | ||||
| Shares Owned By Institutions | 2.30 % | ||||
| Number Of Shares Shorted | 27.52 K | ||||
| Price To Sales | 18.03 X | ||||
| Revenue | 142 K |
Pair Trading with Serina Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Serina Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Serina Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Serina Stock
Moving against Serina Stock
| 0.73 | GILD | Gilead Sciences | PairCorr |
| 0.71 | BMY | Bristol Myers Squibb | PairCorr |
| 0.62 | DYAI | Dyadic International | PairCorr |
| 0.53 | ESPR | Esperion Therapeutics Buyout Trend | PairCorr |
The ability to find closely correlated positions to Serina Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Serina Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Serina Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Serina Therapeutics to buy it.
The correlation of Serina Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Serina Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Serina Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Serina Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Serina Stock Analysis
When running Serina Therapeutics' price analysis, check to measure Serina Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Serina Therapeutics is operating at the current time. Most of Serina Therapeutics' value examination focuses on studying past and present price action to predict the probability of Serina Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Serina Therapeutics' price. Additionally, you may evaluate how the addition of Serina Therapeutics to your portfolios can decrease your overall portfolio volatility.